Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | MicrobiomeTrials← Back to trialsNCT07535359
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
AVAILABLEEXPANDED_ACCESS
Trial Details
Locations- Central Care Cancer Center, Salina, Kansas, United States
- Duke Cancer Institute, Durham, North Carolina, United States
- University of Texas Southwestern Medical, Dallas, Texas, United States
Other microbiome trials you might be interested in
Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti…
Birmingham, United StatesEst. completion Oct 1, 2029
Nsclc
Prospective, biological, observational study involving the collection and use of samples from patients suffering from NS…
Rome, ItalyEst. completion Jul 24, 2026